**Core tip:** Despite the completion of hepatitis B vaccination, loss of hepatitis B immunity in children after liver transplantation is common and we encountered a case of *de novo* hepatitis B virus (HBV) infection following liver transplantation. Serum anti-HBs, albumin, total bilirubin, and direct bilirubin prior to liver transplantation were identified as potential factors related to HBV immunity loss after liver transplantation. A booster dose of hepatitis B vaccine and raising serum albumin to normal levels could delay the rapid loss of HBV immunity after liver transplantation but may not prevent *de novo* hepatitis B. Consequently, strategies are required to maintain anti-HBs antibody above the protective level after liver transplantation. Regular assessment of anti-HBs after liver transplantation should also be considered along with revaccination to guarantee long-term protection from HBV infection.

INTRODUCTION
============

Hepatitis B virus (HBV) infection is considered a great burden worldwide owing to its chronicity and the increased risk of hepatocellular carcinoma. Moreover, antiviral therapy might not completely eradicate HBV from the human liver\[[@B1]\]. Since the 1980s, primary HBV immunization has been implemented to reduce HBV transmission and has shown high efficacy and good serological correlates for protective immunity\[[@B2],[@B3]\]. The rapid and robust response, which usually develops 5-8 d after re-exposure to the HBsAg and peaks after approximately 14 d, indicates the long-lasting protective property of the vaccine despite the undetectable anti-HBs titer\[[@B4]-[@B6]\]. In contrast, a more rapid decline of anti-HBs antibody level has been observed in children post-liver transplantation compared to healthy children\[[@B7],[@B8]\], which corresponds to a loss of protection as *de novo* HBV infection was evident in some cases\[[@B9]-[@B11]\]. This evidence implied that these immunocompromised patients might need a higher protective level of anti-HBs antibody with which to prevent HBV infection following liver transplantation\[[@B11]-[@B14]\].

The assessment of anti-HBs titers is recommended in patients who have undergone liver transplantation\[[@B12]-[@B14]\], but there is a lack of data regarding an appropriate schedule for revaccination. Moreover, there is insufficient data supporting the disease burden of *de novo* hepatitis B infection after liver transplantation, especially if the liver is from an antiHBc-negative donor\[[@B9],[@B10]\].

The present study aimed to assess anti-HBs immunity loss in children who received primary vaccination and also possessed anti-HBs immunity above the protective level prior to liver transplantation. In addition, we also present a case of *de novo* hepatitis B infection after liver transplantation despite the fact that the patient had high titers of pre-transplantation anti-HBs and received an anti-HBc-negative liver from his father.

MATERIALS AND METHODS
=====================

Recruitment of participants
---------------------------

All children who underwent liver transplantation and received ≥ 3 doses of hepatitis B vaccine prior to transplantation between May 2001 and June 2017 were invited to participate in this study. Participants over 18 years of age at the time of the study and with no history of anti-HBs or anti-HBs \< 10 IU/L before liver transplantation were excluded. Medical records were retrospectively reviewed to collate the following information: (1) demographic data \[gender, age, body weight (BW), height, body mass index (BMI)\] and (2) history of hepatitis B vaccination and booster prior to liver transplantation. Furthermore, the pediatric end-stage liver disease (PELD) score, or the model for end-stage liver disease (MELD) score, was calculated in children aged ≤ 13 years old and \> 13 years old at the time of liver transplantation, respectively, every 3 mo after children were placed on the transplant waiting list. The current PELD/MELD score at the time of albumin infusion has not been initiated was used for data analysis. Laboratory data that might reflect immune status and disease severity was collated, including complete blood count, albumin, total bilirubin (TB), direct bilirubin (DB), immunosuppressant use and hepatitis B profiles before/after transplantation (HBsAg, anti-HBs, and anti-HBc). Follow-up time and donor characteristics were also collated, including gender; hepatitis B profiles (HBsAg, anti-HBs, and anti-HBc), and also whether the donor was alive or cadaveric. Samples were obtained from all participants who did not undergo hepatitis B profile testing after transplantation. Nutritional status (BW, height, BMI) and immunosuppressant use at the same time of hepatitis B profile testing were also recorded. Participants were classified into two subgroups: immune and non-immune. Hepatitis B immunity was defined as when anti-HBs level \> 10 IU/L. *De novo* hepatitis B infection was defined as positive HBsAg and HBV DNA serological tests after liver transplantation despite a negative test prior to transplantation. A high anti-HBs titer was defined as when anti-HBs \> 1000 IU/L.

Ethical considerations
----------------------

Routine history taking and physical examination, including weight and height measurement, were carried out by physicians. Anti-HBs, anti-HBc, and HBsAg were tested concurrent with routine laboratory testing during the follow-up visit to the transplant clinic. Verbal consent was obtained from the caregivers. Ethical approval was granted by the Ethics Committee, Faculty of Medicine, Chulalongkorn University (IRB number: 614/60).

Statistical analysis
--------------------

Continuous and categorical data were presented as mean ± SD/median (range) and proportion or percentage, respectively. The Mann-Whitney *U* test and unpaired *t*-test were used to compare continuous data, as appropriate. The Chi-square test was used to compare categorical data. Analysis of variance (ANOVA) was used to compare more than 2 continuous variables. Multiple linear regression was performed to investigate the influence of significant parameters on the loss of anti-HBs after liver transplantation. A *P*-value \> 0.05 was regarded as being statistically significant. Data analyses were performed using SPSS version 24.0.0 (SPSS, Inc., Chicago, IL, United States).

RESULTS
=======

Recipient and donor characteristics
-----------------------------------

Seventy-two children underwent liver transplantation between May 2001 and June 2017. All children were negative for HBsAg. Twenty-two cases were excluded for the following reasons: incomplete anti-HBs data (*n* = 12), anti-HBs \< 10 IU/L (*n* = 8) before transplantation, and age \> 18 years (*n* = 2). Finally, 50 children were recruited into the present study with a mean age of 6.67 ± 4.63 years; 54% were female (Figure [1](#F1){ref-type="fig"}). The indications for liver transplantation were biliary atresia (*n* = 39), Alagille syndrome (*n* = 2), progressive familial intrahepatic cholestasis (PFIC) (*n* = 2), primary bile acid deficiency (*n* = 1), fulminant Wilson's disease (*n* = 1), hepatoblastoma (*n* = 1), glycogen storage disease (*n* = 1) and cryptogenic cirrhosis (*n* = 3). All children received primary hepatitis B vaccination at birth and at 1 and 6 mo of age. Twenty-three subjects received one booster dose 1-2 mo before transplantation. Twenty-three subjects had high anti-HBs (\> 1000 IU/L) before liver transplantation. Most subjects received a living donor liver transplantation from their parents (*n* = 44, 88%), while 6 (12%) received a liver from a cadaveric donor. Children who received an anti-HBc-positive liver from the 6 cadaveric donors were required to take lifelong lamivudine. The severity of chronic liver disease, or PELD score and MELD score, were 18.38 ± 8.47 (*n* = 47) and 15 (range: 11-19; *n* = 3), respectively. All children received at least two immunosuppressants early after transplantation and only one immunosuppressant subsequently, with the exception of immunosuppressive agent-withdrawal in one female patient. This particular patient developed post-transplantation lymphoproliferative disease (PTLD) and ongoing cholestasis, and is thus awaiting re-transplantation. The clinical and demographic characteristics of all participants and donors are shown in Table [1](#T1){ref-type="table"}.

###### 

Patients' demographic data and characteristics mean ± SD or *n* (%)

  **Characteristics**                               **All participants (*n* = 50)**
  ------------------------------------------------- ---------------------------------
  Age (yr)                                          6.67 ± 4.63
  Age at liver transplantation (yr)                 3.06 ± 3.97
  Gender - female                                   27 (54)
  Before liver transplantation                      
  Anti-HBs level (IU/L)                             584.41 ± 415.45
  Anti-HBc positive                                 1 (2)
  After liver transplantation                       
  Anti-HBs level (IU/L)                             58.56 ± 6.40
  Length of stay in hospital after transplant (d)   44.10 ± 29.30
  ABO incompatibility                               3 (6)
  PELD/MELD score                                   18.38 ± 8.47/15 (11-19)
  Time since transplantation (yr)                   2.53 ± 2.11
  Medical complications                             
  Acute rejection                                   22 (44)
  Cytomegalovirus infection                         15 (30)
  Posttransplant lymphoproliferative disorder       14 (28)
  *De novo* hepatitis B infection                   1 (2)
  *De novo* food allergy                            9 (18)
  Surgical complications                            
  Vascular stricture                                20 (40)
  Biliary stricture                                 12 (24)
  Chylous ascites/chylothorax                       7 (14)
  Donor characteristics                             
  Gender - female                                   22 (44)
  Cadaveric                                         6 (12)
  Living                                            44 (88)
  Anti-HBs                                          
  Negative                                          13 (26)
  Positive                                          
  1-9 IU/L                                          30 (60)
  \> 10 IU/L                                        7 (14)
  Anti-HBc positive                                 6 (12)

PELD: Pediatric end-stage liver disease; MELD: Model for end-stage liver disease.
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Recipient anti-HBs before and after liver transplantation
---------------------------------------------------------

Anti-HBs titers before and after liver transplantation were 584.41 ± 415.45 and 58.56 ± 6.40 IU/L, respectively. Thirty participants (60%) experienced the loss of HBV immunity after transplantation. The rates of non-immunity (anti-HBs \< 10 IU/L) in the participants were 46% (*n* = 26) at one year, 57% (*n* = 7) at two years and 82% (*n* = 17) at \> three years following liver transplantation. The age at liver transplantation and the time from transplant to anti-HBs testing were 3.06 ± 3.97 years and 2.53 ± 2.11 years, respectively. One patient was diagnosed with *de novo* hepatitis B infection three years after liver transplantation.

Nutritional status, disease severity and the immune status of subjects before and after liver transplantation
-------------------------------------------------------------------------------------------------------------

After transplantation, the body weight and height, not including BMI, were increased compared to pre-transplant status (*P* \< 0.001). TB, DB, and albumin levels, which were reflective of disease severity, improved after liver transplantation in both the short-term (at 3 mo) and long-term (2.53 ± 2.11 years; *P* \< 0.001). With respect to immune status, white blood cell count (*P* = 0.002), neutrophils (*P* \< 0.001) and lymphocytes (*P* = 0.01) were reduced, while platelet count (*P* = 0.005) increased after liver transplantation, in both the short-term (at 3 mo) and long-term (2.53 ± 2.11 years). The number of prescribed immunosuppressants decreased in the long-term post-liver transplantation (*P* \< 0.001; Table [2](#T2){ref-type="table"}).

###### 

Nutritional and laboratory results of pre and post liver transplantation mean ± SD or *n* (%)

                                **Pre-transplantation**   **Post-transplantation**   ***P* value**    
  ----------------------------- ------------------------- -------------------------- ---------------- ----------
  Body weight (kg)              11.66± 8.01               \-                         21.32 ± 12.07    \< 0.001
  Height (meter)                0.81 ± 0.23               \-                         1.07 ± 0.28      \< 0.001
  BMI (kg/m^2^)                 16.59 ± 1.67              \-                         16.63 ± 2.71     0.76
  Complete blood count                                                                                
  White blood cell (/μL)        10492 ± 4627              8559 ± 2495                7729 ± 3843      0.002
  Neutrophil (/μL)              4938 ± 2565               3385 ± 1679                3418 ± 1912      \< 0.001
  Lymphocyte (/μL)              4263 ± 2222               3982 ± 1722                3109 ± 1762      0.01
  Platelet (/μL)                172880 ± 94557            199720 ± 82777             233957 ± 94136   0.005
  Liver function test                                                                                 
  Total bilirubin(mg/dL)        18.50 ± 12.68             2.41 ± 0.91                0.84 ± 0.91      \< 0.001
  Direct bilirubin (mg/dL)      13.41 ± 10.28             0.83 ± 0.71                0.38 ± 0.51      \< 0.001
  Albumin (g/dL)                3.29 ± 0.97               3.94 ± 0.48                4.08 ± 0.35      \< 0.001
  Number of immunosuppressant                                                                         
  0                             0                         1 (2)                                       
  1                             5 (10)                    27 (54)                    \< 0.001         
  2                             23 (46)                   17 (34)                                     
  3                             22 (44)                   5 (10)                                      

BMI: Body mass index.

Comparing participants with HBV immunity and loss of immunity
-------------------------------------------------------------

The age at transplantation and the time of anti-HBs testing after transplantation were lower in participants with HBV immunity (5.27 ± 3.74 years and 2.09 ± 2.03 years, respectively) than in those with loss of HBV immunity (7.60 ± 4.98 years and 3.71 ± 4.78 years, respectively; *P* = 0.082). No significant differences were observed in terms of BW, height, and BMI that might reflect the nutritional status of either of the groups. In terms of disease severity, participants with HBV immunity had a lower PELD score (*P* = 0.086), TB (*P* = 0.003), DB (*P* \< 0.001), and higher albumin (*P* = 0.04) levels. There were no differences in terms of white blood cell, neutrophil or lymphocyte count before and in the short- or long-term since liver transplantation. Even the number of prescribed immunosuppressants decreased in the long-term after liver transplantation, and there was no difference between the two groups in this respect. We further studied the effect of a booster vaccine before liver transplantation, as twenty-three patients received the booster vaccine. Of these, 14 (61%) still had HBV immunity while 9 (39%) showed a loss in HBV immunity. Twenty-seven patients did not receive the booster vaccine before liver transplantation; of these, six (22%) still had HBV immunity while 21 (78%) did not. We compared all potential factors associated with the loss of HBV immunity between patients who received a booster dose with (*n* = 14) and without HBV immunity (*n* = 9), and there were no significant differences with respect to any of the parameters tested (Table [2](#T2){ref-type="table"}). One patient who received a booster dose, and whose anti-HBs was more than 1000 IU/L before liver transplantation, was diagnosed with *de novo* hepatitis three years and ten months after liver transplantation (Table [3](#T3){ref-type="table"}).

###### 

Potential factors associated with immunity in participants with HBV immunity and immunity loss mean ± SD or *n* (%)

                                                            **Nonimmunity (*n* = 30)**   **Immunity (*n* = 20)**   ***P* value**
  --------------------------------------------------------- ---------------------------- ------------------------- ---------------
  Age (yr)                                                  7.60 ± 4.98                  5.27 ± 3.74               0.08
  Age at liver transplantation (yr)                         3.71 ± 4.78                  2.09 ± 2.03               0.11
  Gender:Female                                             15 (50)                      12 (60)                   0.58
  Body weight (kg)                                          13.07 ± 9.91                 9.56 ± 2.74               0.07
  Height (m)                                                0.85 ± 0.28                  0.75 ± 0.12               0.09
  Body mass index (kg/m^2^)                                 16.45 ± 1.62                 16.45 ± 1.62              0.47
  Anti-HBs level before transplantation (IU/L)              441.39 ± 408.88              798.94 ± 330.47           0.24
  Length of hospital stay after transplantation (d)         47.77 ± 34.89                38.80 ± 17.45             0.24
  PELD/MELD score                                           20.19 ± 8.50 (*n* = 28)      15.90 ± 7.98 (*n* = 19)   0.09
  Time since transplant to anti-HBs testing (yr)            2.83 ± 2.00                  2.06 ± 2.22               0.22
  Donor characteristics                                                                                            
  Gender: Female                                            14 (47)                      8 (40)                    0.43
  Living                                                    26 (87)                      18 (90)                   0.54
  Medical complication                                                                                             
  Acute rejection                                           11 (37)                      11 (55)                   0.16
  CMV infection                                             6 (20)                       9 (45)                    0.11
  PTLD                                                      7 (23)                       7 (35)                    0.28
  *De novo* hepatitis B                                     1 (3)                        0 (0)                     0.65
  *De novo* food allergy                                    5 (16)                       4 (20)                    0.52
  Surgical complication                                                                                            
  Vascular stricture                                        13 (43)                      7 (35)                    0.39
  Biliary stricture                                         8 (27)                       4 (20)                    0.46
  Chylous ascites/chylothorax                               5 (17)                       2 (10)                    0.41
  Laboratory data before transplantation                                                                           
  White blood cell (/µL)                                    10237 ± 4167                 10875 ± 5334              0.63
  Neutrophil (/µL)                                          4780 ± 2137                  5174 ± 3145               0.60
  Lymphocyte (/µL)                                          4372 ± 2515                  4100 ± 1742               0.65
  Platelet (/µL)                                            159366 ± 99431               193156 ± 85132            0.22
  Total bilirubin (mg/dL)                                   22.80 ± 13.72                12.04 ± 7.37              0.003
  Direct bilirubin (mg/dL)                                  16.51 ± 11.37                8.73 ± 6.08               0.001
  Albumin (g/dL)                                            3.07 ± 0.65                  3.63 ± 1.25               0.04
  Laboratory data 3 mo after transplantation                                                                       
  White blood cell (/µL)                                    8312 ± 2596                  8931 ± 3440               0.64
  Neutrophil (/µL)                                          3221 ± 1307                  3630 ± 2136               0.45
  Lymphocyte (/µL)                                          3879 ± 1851                  4136 ± 1542               0.61
  Platelet (/µL)                                            193300 ± 86221               208600 ± 78591            0.53
  Albumin (g/dL)                                            3.96 ± 0.51                  3.91 ± 0.44               0.72
  Total bilirubin (mg/dL)                                   0.99 ± 1.12                  0.59 ± 0.35               0.07
  Direct bilirubin (mg/dL)                                  0.37 ± 0.15                  0.32 ± 0.17               0.12
  Laboratory data after long-term transplantation                                                                  
  White blood cell (/µL)                                    7114 ± 2845                  8815 ± 5083               0.22
  Neutrophil (/µL)                                          3196 ± 1412                  3809 ± 2576               0.38
  Lymphocyte (/µL)                                          3039 ± 1553                  3232 ± 2128               0.72
  Platelet (/µL)                                            217033 ± 87395               263823 ± 100739           0.12
  Albumin (g/dL)                                            4.12 ± 0.35                  4.00 ± 0.35               0.26
  Total bilirubin (mg/dL)                                   0.98 ± 1.10                  1.10 ± 0.31               0.08
  Direct bilirubin (mg/dL)                                  0.45 ± 0.62                  0.25 ± 0.13               0.20
  Immunosuppressant 3 mo after transplantation                                                                     
  None                                                      0                            0                         
  1                                                         3 (10)                       2 (10)                    0.41
  2                                                         16 ((53)                     7 (35)                    
  3                                                         11 (37)                      11 (50)                   
  Immunosuppressant after long-term liver transplantation                                                          
  None                                                      1 (3)                        0                         
  1                                                         17 (56)                      10 (50)                   0.77
  2                                                         9 (30)                       8 (40)                    
  3                                                         3 (10)                       2 (10)                    

PELD: Pediatric end-stage liver disease; MELD: Model for end-stage liver disease; PTLD: Post-transplantation lymphoproliferative disease.

A patient with de novo hepatitis B
----------------------------------

A five-year-old boy with biliary cirrhosis and an unsuccessful Kasai's operation underwent liver transplantation at 14 mo of age; his anti-HBc-negative father was the donor. He received 4 doses of HBV vaccine prior to liver transplantation, and his pre-existing anti-HBs antibody titer was \> 1000 IU/L. His parent's viral profiles were negative for HBV infection (HBsAg, anti-HBc, and anti-HBs were all negative). After liver transplantation, he developed stenosis at the hepatic artery leading to the inferior vena cava anastomosis and underwent venoplasty with balloon dilatation three times. Furthermore, he was given subcutaneous enoxaparin injections every 12 h for 5 mo and transfused 20 times with blood components. Three years and ten months after the liver transplantation, transaminitis was detected, with positive tests for HBsAg, HBeAg, and anti-HBc (2169.61, 1706, and 8.45, respectively; cutoff value: \< 1.00), and an HBV viral load of 33212320 IU/mL. The timeline of this patient is shown in Figure [2](#F2){ref-type="fig"}.

![Timeline of the case report from pre-liver transplantation to diagnosis of HBV infection. HBV: Hepatitis B virus.](WJG-24-752-g002){#F2}

Several possible routes of HBV infection after liver transplantation were investigated. His father and mother were both tested for HBsAg, anti-HBc, and anti-HBs titers and serum HBV viral load; all results were negative. There were no apparent HBsAg carriers in the patient's family. Another strong possibility might be from blood transfusion, in which the blood component was partly derived from a recently infected donor. However, the handling of blood and blood products in Thailand is extremely safe, as we employ the universally-accepted nucleic acid amplification test (NAT) to screen for HBV, hepatitis C virus, and HIV from all blood donors. All 15 donors who donated blood to this patient had undergone repeat NAT-based HBV testing and none had any evidence of HBV occult infection. The *de novo* activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation has been documented previously, however, no vaccine escape mutants were found when the HBs gene was screened in our patient (Figure [3](#F3){ref-type="fig"}).

![Amino acid sequence of "a" determinant of the HBs gene (position 110-160) showing no significant escape mutants in common regions (T126S/N, Q129H, D144A, and G145R).](WJG-24-752-g003){#F3}

DISCUSSION
==========

Transmission of the HBV core from hepatitis B core antibody-positive donors was first reported in 1998 by Uemoto et al\[[@B15]\]. In Uemoto et al's, HBV existing in the liver of healthy donors who were hepatitis B core antibody-positive, but not in the blood, was shown to be transmitted to recipients by liver grafts following liver transplantation. Moreover, livers from hepatitis B core antibody-positive donors exerted influence on graft survival as this was lower in the recipients of hepatitis B core antibody-positive tissue compared to those receiving tissue from hepatitis B core antibody-negative donors, especially among HBsAg-negative recipients\[[@B16]\]. As a result, robust strategies have been developed to prevent viral activation and *de novo* hepatitis B infection in recipients receiving liver grafts from hepatitis B core antibody-positive donors. These strategies involve passive immunization with hyper-immune hepatitis B immunoglobulin (HBIG), with or without antiviral agent, or the administration of hepatitis B vaccine\[[@B17]-[@B20]\]. In contrast, the prevention of *de novo* hepatitis B infection in recipients of tissue from hepatitis B core antibody-negative donors has generally been disregarded because evidence to support *de novo* hepatitis B infection from the loss of HBV immunity after liver transplantation is scarce\[[@B9],[@B10]\].

In this study, we report a high prevalence of the loss of HBV immunity following liver transplantation, and its association with disease severity and anti-HBs titer levels before liver transplantation. Our study demonstrated that 60% of pediatric liver transplant patients who were previously immunized were non-immune after their transplants. This was comparable to the 67% of patients reported in a previous study who also showed a loss of immunity\[[@B8]\]. While patients with HBV immunity had a significantly higher titer of anti-HBs before liver transplantation than participants showing a loss of HBV immunity after liver transplantation, a higher titer of anti-HBs before liver transplantation cannot guarantee protective HBV immunity following liver transplantation, as evidenced by the case report described in the present study. This finding contrasts with a previous study by Su et al\[[@B9]\] who reported that an anti-HBs titer of \> 200 IU/L before liver transplantation might be sufficient to prevent *de novo* HBV infection in an HBsAg-negative recipient. One possible cause of HBV infection in our patient is that the loss of HBV immunity could have occurred after liver transplantation at a time when the patient was most likely exposed to HBV. Our data also showed a rapid reduction in the level of anti-HBs after liver transplantation with titers below the protective threshold. Regular assessment of anti-HBs, and revaccination after liver transplantation, should therefore be considered to maintain the anti-HBs titer level above the protective threshold and therefore prevent *de novo* hepatitis B. Lin et al\[[@B10]\] recommended maintaining a high level of anti-HBs (\> 1000 IU/L), which may prevent *de novo* HBV infection in pediatric patients undergoing liver transplantation who had efficient primary vaccination. A booster vaccine appears to be the most simple and effective regimen with which to maintain high titers of anti-HBs. However, this previous study reported that patients had to receive 1-19 injections, within a period of 4-42 mo after liver transplantation to maintain adequate titers\[[@B10]\]. Potential factors for the rapid loss of anti-HBs loss should therefore be considered in order to avoid patients undergoing multiple injections.

In the present study, anti-HBs level, cholestasis, and low albumin levels before liver transplantation were identified to be significant factors contributing to the loss of immunity after liver transplantation. Contrast to a previous study that found statistical significance in terms of age or time since liver transplantation instead\[[@B8]\]. Anti-HBs level before liver transplantation may represent one of the main factors with which to predict the loss of anti-HBs after liver transplantation; age and time since liver transplantation should not be relied upon. Although the hepatitis B vaccine is highly immunogenic and very effective, there is a gradual reduction of anti-HBs titer to below the protective threshold after one or two decades of life, even in healthy individuals\[[@B21],[@B22]\]. In children with chronic liver diseases, anti-HBs immunity decreases more rapidly than in healthy children, as demonstrated in the present study; indeed, at least 8 of the 72 children on the waiting list for liver transplantation in our institution had anti-HBs \< 10 IU/L and were excluded from the present study. In a previous study, Leung et al\[[@B8]\] stated that a major limitation of their study was that they could not definitively state whether the loss of HBV immunity in their study was due to a loss of immunity before or after transplantation. We believe that the present study has addressed this shortfall by focusing on anti-HBs level before liver transplantation and then divided patients into high- and low-titer groups. A booster vaccine before liver transplantation is necessary in order to maintain a higher titer of anti-HBs in children following liver transplantation. However, the cutoff for a protective anti-HBs level that is more than 10 IU/L after vaccination might not be enough to protect these vulnerable patients from HBV\[[@B23]\], owing to the rapid decline of anti-HBs over time. Further functional cellular studies are now required to address the most appropriate cutoff level for the protective threshold of anti-HBs in children following liver transplantation.

However, it is not just strategies to delay HBV immunity loss that are needed; we also need to develop methods to re-establish active immunity against HBV after liver transplantation. Lu et al\[[@B20]\] reported the improved feasibility of vaccination combined with nucleoside analogues in the prevention of HBV reinfection after orthotopic liver transplantation compared to regular HBIG administration. In this previous study, long-term and repetitive vaccine stimulation was shown to be an important method with which to create and cultivate an enhanced immune response in these immunocompromised patients. Similar to this study, a few pediatric studies have reported the use of intermittent vaccination reinforcement, or booster vaccination, to maintain spontaneous anti-HBs production in children after liver transplantation\[[@B10],[@B24],[@B25]\]. For example, Ni\[[@B25]\] studied both the humoral and cellular immunity of booster hepatitis B vaccines in children after liver transplantation and demonstrated that the immunological response following a booster dose appeared to be adequate, at least over the short term (2 mo assessment period). However, Bauer et al\[[@B26]\] conducted a pilot study of cellular immune response investigating HBsAg-specific T and B cells in adults after liver transplantation compared with controls and highlighted the role of the strong inhibitory effect of regulatory T cells upon immunological response after hepatitis B revaccination over a period of long term assessment (\> one year). The best rationale for HBV revaccination in liver transplantation patients has yet to be elucidated. Future studies are required to identify an appropriate HBV immunization protocol for children after liver transplantation which will effectively re-establish both cellular and humoral immunities to HBV.

Other predictive parameters responsible for rapid anti-HBs loss are cholestasis and low albumin levels. Low albumin levels might reflect the poor synthetic function of the liver, or severe malnutrition, or both. A previous study confirmed that albumin infusion could restore the immunological function of patients with decompensated cirrhosis by increasing circulating PGE~2~, a potent immunomodulator, both *in vitro* and *in vivo*\[[@B27]-[@B29]\]. However, a study by Leung et al\[[@B8]\], and this present study, could not demonstrate a significant difference in terms of disease severity when comparing PELD score between patients in immune and non-immune groups. While the mean PELD score in Leung et al's\[[@B8]\] study was higher than the present study, the mean serum albumin level, which is one of the parameters used to calculate the PELD score, was in the upper normal level in Leung et al's\[[@B8]\] study compared to the low albumin level in the present study. This upper normal level of serum albumin might imply that the subjects involved in this previous study had already received albumin infusion at the time of data collection. In the present study, we evaluated the PELD score every three months from when the patients joined the waiting list for transplantation and chose the most recent PELD score, at which point, albumin infusion had not been initiated. One limitation of our method is that our PELD score might be lower than the actual PELD score prior to liver transplantation; however, we obtained actual serum albumin data for analysis and that might be why our data showed lower PELD scores, with significantly low albumin levels in patients with anti-HBs loss, than the data reported by Leung et al\[[@B8]\]. As a result, while waiting for liver transplantation, albumin infusion is an effective treatment option to treat not only hepatorenal syndrome and spontaneous bacterial peritonitis, but also gain better immunity; this practice represents common practice for most chronic liver diseases in children.

In the present study, we were unable to demonstrate a significant effect of nutritional status upon anti-HBs immunity after liver transplantation. In our transplant unit, children were not routinely tested for lipid soluble vitamins A, D, and E. Furthermore, body weight and BMI are not the best parameters to perform nutritional assessment, as some children suffered from edema and huge abdominal distension as a result of ascites. Moreover, the immunosuppressants and complications after liver transplantation were not shown to be significantly associated with the loss of anti-HBs; in this respect, our study was consistent with Leung et al\[[@B8]\].

Our study has some limitations which need to be considered, particularly the low number of participants, inadequate data reflect the nutritional status, and the heterogeneity of immunosuppressant-use among patients. A larger, well-designed, multicenter study, using the same protocol of care after liver transplantation, is now needed to validate our present results.

In summary, significant loss of anti-HBs after liver transplantation is unexpectedly common. An anti-HBs level above 1000 IU/L before liver transplantation cannot prevent *de novo* hepatitis B. Boosters or a full-series vaccination is required for children after liver transplantation, concurrent with close monitoring of anti-HBs level. Further studies should aim to identify the best rationale for a HBV re-immunization program based upon strong clinical evidence. The potential factors that can affect anti-HBs levels, and which can be modulated prior to liver transplantation and therefore delay the rapid loss of anti-HBs include booster hepatitis B vaccines and the early administration of albumin.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

A more rapid decline of anti-HBs antibody was observed in children after liver transplantation compared to healthy children who had been previously immunized. The loss of anti-HBs might not indicate a loss of hepatitis B virus (HBV) immunity in healthy subjects. However, viral reactivation and *de novo* hepatitis B infection were clearly demonstrated in an HBsAg-negative recipient who received a liver from hepatitis B core antibody-positive or negative donors, suggesting the loss of HBV protection in such immunocompromised subjects. The present study provided strong evidence of HBV immunity loss in 60% of children after liver transplantation and one case of *de novo* hepatitis B infection. This was despite a high titer of anti-HBs prior to transplantation and the receipt of a hepatitis B core-negative liver. The present study highlighted the importance of developing strategies to re-establish active immunity to HBV following liver transplantation.

Research motivation
-------------------

HBV infection in patients after liver transplantation can lead to chronic hepatitis, shorter graft survival and graft loss. However, a routine strategy for HBV reimmunization after liver transplantation, and an appropriate cutoff for the prevention of *de novo* hepatitis B infection, have yet to be elucidated. This study demonstrated a decline of anti-HBs level after liver transplantation and provided valuable data relating to the factors which can affect the rapid loss of anti-HBs and which can be modulated before liver transplantation in order to delay rapid anti-HBs loss. Such factors include booster hepatitis B vaccines and the early administration of albumin. A revaccination program is recommended for children after liver transplantation in order to re-establish active immunity to HBV.

Research objectives
-------------------

Regular assessment of anti-HBs and revaccination after liver transplantation to maintain an anti-HBs titer level above the protective threshold should be considered to prevent *de novo* hepatitis B. Further studies should aim to identify the best rationale for a reimmunization program to effectively re-establish active immunity to HBV.

Research methods
----------------

The authors enrolled a total of 50 children who had undergone liver transplantation between May 2001 and June 2017. Demographic data, types of donor and liver transplant, anti-HBs level, time since liver transplantation, complications and immunosuppressant-use were collated and analyzed using SPSS version 24.0.0 software. To this end, the authors reported an observational study of a five-year-old boy who had received full HBV vaccination previously, underwent liver transplantation with his father's anti-HBc-negative liver, but was then diagnosed with *de novo* hepatitis B three years after transplantation.

Research results
----------------

The authors found that the loss of hepatitis B immunity after liver transplantation was unexpectedly common and that 60% of subjects had an anti-HBs level \< 10 IU/L after a mean period of 2.53 years after transplantation. The potential factors relating to the loss of HBV immunity were anti-HBs (*P* = 0.002), serum albumin *(P* = 0.04), total bilirubin (*P* = 0.001) and direct bilirubin (*P* = 0.003) prior to liver transplantation. We also report a case of *de novo* hepatitis B, who received a hepatitis B core antibody-negative liver from his father, and had a high titer of anti-HBs (\> 1000 IU/L) prior to transplantation. Future studies should aim to develop strategies to re-establish active immunity to HBV after liver transplantation.

Research conclusions
--------------------

The new findings of this study are the high prevalence of hepatitis B immunity loss, and a case report of *de novo* hepatitis B, in a previously immunized recipient who received a liver from a hepatitis B core antibody-negative donor. *De novo* hepatitis B in a previously immunized recipient who received a liver from a hepatitis B core antibody-negative donor, could have been initiated when exposed to HBV during the period following transplantation coincident with the loss of HBV immunity. High anti-HBs loss after liver transplantation is unexpectedly common. High anti-HBs (\> 1000 IU/L) prior to liver transplantation cannot prevent *de novo* hepatitis. Serum anti-HBs, albumin, total bilirubin and direct bilirubin prior to liver transplantation were the potential factors associated with the loss of HBV immunity after liver transplantation. Anti-HBs levels below the protective level in children after liver transplantation might reflect the loss of immunity or the loss of protection against HBV. A re-immunization program for all liver-transplanted children in order to prevent *de novo* hepatitis B. Disease severity, nutritional status, immune status and HBV immunity as a result of HBV immunization might represent potential factors to consider for re-establishing active HBV immunity following liver transplantation. *De novo* hepatitis B could have occurred after liver transplantation at a point when the recipient was likely to have been exposed to HBV.

Research perspectives
---------------------

Re-assessment of anti-HBs levels and vaccination to maintain levels of anti-HBs above the protective level might prevent de novo hepatitis B after liver transplantation. Studying the immunological response of HBsAg-specific T and B cells following HBV exposure in order to establish an appropriate cutoff for the protective level of anti-HBs to prevent HBV infection in children after liver transplantation will be merit. Moreover, setting up an appropriate HBV immunization protocol to re-establish active HBV immunity by assessing cellular and humoral immunity response after HBV immunization protocols over short- and long-term follow-up periods also should be considered.
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